Corcept Therapeutics, Inc.
Corcept Therapeutics, Inc. Patent applications | ||
Patent application number | Title | Published |
---|---|---|
20140179671 | FUSED RING AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS - The present invention provides a novel class of fused ring azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators. | 06-26-2014 |
20140038926 | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators - The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators. | 02-06-2014 |
20140005158 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | 01-02-2014 |
20130245266 | SOLID FORMS AND PROCESS FOR PREPARING - The present invention provides amorphous solid forms of the compound of Formula I, as well as methods for preparing the compound of Formula I by precipitation. | 09-19-2013 |
20130225633 | PHENYL HETEROCYCLOALKYL GLUCOCORTICOID RECEPTOR MODULATORS - The present invention provides phenyl-heterocycloalkyl fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators. | 08-29-2013 |
20130131030 | OPTIMIZING MIFEPRISTONE ABSORPTION - The present invention provides a method for altering the pharmacokinetics of mifepristone upon oral administration. Mifepristone absorption into the blood is increased upon administration with meals. The method of the invention can benefit patients suffering from conditions including psychiatric illnesses and hormonal disorders. | 05-23-2013 |
20130072486 | PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS - The present invention provides a class of pyrimidinedione cyclohexyl compounds and methods of using these compounds as glucocorticoid receptor modulators. | 03-21-2013 |
20120225856 | FUSED RING AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS - The present invention provides a novel class of fused ring azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators. | 09-06-2012 |
20120220565 | PYRIDYL-AMINE FUSED AZADECALIN MODULATORS - The present invention provides a novel class of pyridyl-amine fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators. | 08-30-2012 |
20110294771 | TREATMENT OF MUSCULAR DYSTROPHY - The present invention resides in the discovery that glucocorticoid receptor antagonists are effective for treating muscular dystrophy including type 1 or type 2 myotonic dystrophy. Treatment methods and kits are provided. | 12-01-2011 |
20110166115 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS - The invention generally pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptor can be used in methods for treating patients diagnosed with Amyotrophic Lateral Sclerosis (ALS). | 07-07-2011 |
20110166110 | Fused Ring Azadecalin Glucocorticoid Receptor Modulators - The present invention provides a novel class of fused ring azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators. | 07-07-2011 |
20110144072 | Antiglucocorticoid Therapy for the Prevention of Neurological Damage in Premature Infants - This invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for preventing neurological damage associated with glucocorticoid therapy in ventilator-dependent low birth weight preterm infants. Mifepristone, a potent glucocorticoid receptor antagonist, can be used in these methods. | 06-16-2011 |
20100292477 | SOLID FORMS AND PROCESS FOR PREPARING - The present invention provides amorphous solid forms of the compound of Formula I, as well as methods for preparing the compound of Formula I by precipitation. | 11-18-2010 |
20100179115 | USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 - The invention pertains to the discovery that type II glucocorticoid receptor antagonists can be used in methods for reversing or inhibiting the symptoms of depression in patients receiving interleukin-2 treatment. | 07-15-2010 |
20100120759 | AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS - The present invention provides a novel class of azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators. | 05-13-2010 |
20090275600 | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS - The present invention provides a novel class of modified pyrimidine compounds and compositions and methods of using the compounds as glucocorticoid receptor modulators. | 11-05-2009 |
20090062248 | OPTIMIZING MIFEPRISTONE LEVELS IN PLASMA SERUM OF PATIENTS SUFFERING FROM MENTAL DISORDERS TREATABLE WITH GLUCOCORTICOID RECEPTOR ANTAGONISTS - The present invention provides a method for optimizing levels of mifepristone in a patient suffering from a mental disorder amenable to treatment by mifepristone. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1300 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1300 ng/mL. | 03-05-2009 |
20090029959 | Antiglucocorticoid Therapy for the Prevention of Neurological Damage in Premature Infants - This invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for preventing neurological damage associated with glucocorticoid therapy in ventilator-dependent low birth weight preterm infants. Mifepristone, a potent glucocorticoid receptor antagonist, can be used in these methods. | 01-29-2009 |